Variation in platelet function testing has a major influence on detection of aspirin resistance in healthy subjects

Pathophysiology of Haemostasis and Thrombosis

Volumn 36, Issue 2, 2008, Pages 84-90

  Božič Mijovski, Mojca ^a   Rakuša, Matej ^a   Stegnar, Mojca ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Aspirin resistance; Biological variation; Closure time; Platelet aggregation; Platelet function

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; ARACHIDONIC ACID; COLLAGEN; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD CLOTTING PARAMETERS; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OPTICAL PLATELET AGGREGOMETRY; PRIORITY JOURNAL; RELIABILITY; THROMBOCYTE AGGREGATION;

ADULT; ASPIRIN; BLEEDING TIME; DIAGNOSTIC ERRORS; DRUG MONITORING; DRUG RESISTANCE; FEMALE; HUMANS; MALE; NEPHELOMETRY AND TURBIDIMETRY; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; REPRODUCIBILITY OF RESULTS;

EID: 58549103731     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000173727     Document Type: Article

References (27)

1. Antithrombotic Trialist' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
2. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, Hirsh J, Roth G: Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001;119:39S-63S.
3. Hankey GJ, Eikelboom JW: Aspirin resistance. Lancet 2006;367:606-617.
4. Born GV: Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927-929.
5. Nicholson NS, Panzer-Knodle SG, Haas NF, Taite BB, Szalony JA, Page JD, Feigen LP, Lansky DM, Salyers AK: Assessment of platelet function assays. Am Heart J 1998;135:S170-S178.
6. Breddin HK: Can platelet aggregometry be standardized? Platelets 2005;16:151-158.
7. Feuring M, Schultz A, Losel R, Wehling M: Monitoring acetylsalicylic acid effects with the platelet function analyzer PFA-100. Semin Thromb Hemost 2005;31:411-415.
8. Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ: PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195-202.
9. Cattaneo M: Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost 2007;5(suppl 1):230-237.
10. Zeidan AM, Kouides PA, Tara MA, Fricke WA: Platelet function testing: state of the art. Exp Rev Cardiovasc Ther 2007;5:955-967.
11. Fraser CG, Hyltoft Peterson P, Larsen ML: Setting analytical goals for random analytical error in specific clinical monitoring situations. Clin Chem 1990;36:1625-1628.
12. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ: Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-235.
13. Cattaneo M: Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004;24:1980-1987.
14. Moffat KA, Ledford-Kraemer MR, Nichols WL, Hayward CP: Variability in clinical laboratory practice in testing for disorders of platelet function: results of two surveys of the North American Specialized Coagulation Laboratory Association. Thromb Haemost 2005;93:549-553.
15. Zhou L, Schmaier AH: Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field. Am J Clin Pathol 2005;123:172-183.
16. Haubelt H, Anders C, Vogt A, Hoerdt P, Seyfert UT, Hellstern P: Variables influencing Platelet Function Analyzer-100 closure times in healthy individuals. Br J Haematol 2005;130:759-767.
17. Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, Mimuro J, Ozaki Y, Sakata Y: Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 2006;4:1271-1278.
18. Hevelow ME, McKenzie SM, Siegel JE: Reproducibility of platelet function testing. Lab Hematol 2007;13:59-62.
19. Fontana P, Nolli S, Reber G, De Moerloose P: Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost 2006;4:813-819.
20. Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W: Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000;83:316-321.
21. Roller RE, Dorr A, Ulrich S, Pilger E: Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100. Blood Coagul Fibrinolysis 2002;13:277-281.
22. Klein Gunnewiek JM, Hovestad-Witterland AH, Vollaard EJ, Fleuren HW, Metz MD: The influence of acetylsalicylic acid intake by healthy volunteers on duplicate PFA-100 measurements. Blood Coagul Fibrinolysis 2005;16:337-340.
23. Poulsen TS, Mickley H, Korsholm L, Licht PB, Haghfelt T, Jorgensen B: Using the Platelet Function Analyzer-100 for monitoring aspirin therapy. Thromb Res 2007;120:161-172.
24. Pamukcu B, Oflaz H, Onur I, Oncul A, Ozcan M, Umman B, Mercanoglu F, Meric M, Nisanci Y: Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). Blood Coagul Fibrinolysis 2007;18:187-192.
25. Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J: Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004;35:175-178.
26. Grau AJ, Reiners S, Lichy C, Buggle F, Ruf A: Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. Stroke 2003;34:849-854.
27. Addad F, Hassine M, Ben Farhat M, Abderrazak F, Chakroun T, Gamra H, Hamdi S, Betbout F, Samama M, Elalamy I: Intra-individual variability of the platelet anti-aggregation effect of aspirin in coronary patients. Arch Mal Coeur Vaiss 2005;98:979-983.